|
Mentor Corporation announced today that it has taken the first steps toward entry into the U.S. neurological marketplace by completion of enrollment in the Phase I study in its U.S. investigational study of botulinum toxin type A for torticollis/ cervical dystonia
Santa Barbara, CA, USA | June 2, 2008 | Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetics market, announced today that it has taken the first steps toward entry into the U.S. neurological marketplace by completion of enrollment in the Phase I study in its U.S. investigational study of botulinum toxin type A for torticollis/ cervical dystonia.
Joshua H. Levine, President and Chief Executive Officer of Mentor Corporation, commented, "We are very excited about the completion of subject enrollment in this clinical trial. We are now planning the next steps in bringing our purified botulinum toxin type A product to this underserved patient population."
"Based on our participation in this clinical trial, Mentor's product appears to be a well tolerated formulation of botulinum toxin type A," said Dr. Mark Lew, Professor of Neurology at University of Southern California's Keck School of Medicine, Division of Movement Disorders. He further stated, "Patients seem to do well with the doses we have investigated. We anxiously await the results of this double-blind, placebo controlled trial. This product will hopefully offer patients another safe and efficacious alternative therapy for this debilitating condition."
About Mentor Corporation
Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global aesthetics market. The Company develops, manufactures and markets innovative, science-based products for surgical and non-surgical medical procedures that allow patients to retain a more youthful appearance and improve personal well-being. The Company's website is www.mentorcorp.com.
SOURCE: Mentor Corporation |
